Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

PEG MGF vs. Similar Peptides: Side Effect Comparison

Comparing PEG MGF side effects to related peptides provides context for understanding its safety profile relative to other growth factor-based therapies. IGF-1 LR3, another modified IGF-1 variant, shares similar hypoglycemic risks but demonstrates higher rates

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Comparing PEG MGF side effects to related peptides provides context for understanding its safety profile relative to other growth factor-based therapies. IGF-1 LR3, another modified IGF-1 variant, shares similar hypoglycemic risks but demonstrates higher rates of joint discomfort (20-30% vs. 10-15%) and potential for more severe hypoglycemic episodes due to its longer half-life of approximately 20-30 hours compared to PEG MGF's 24-48 hours.
  • PEG MGF
  • IGF-1R activation
  • Injection site reactions (30-40%)
  • <5%
  • Unknown
  • Extended half-life
  • IGF-1 LR3
  • Joint discomfort (20-30%)
  • <1%
  • Higher potency
  • CJC-1295
  • GHRH receptor
  • Injection site reactions (25-35%)
  • Indirect growth factor release
  • Ipamorelin
  • Ghrelin receptor
  • Mild hunger (15-25%)
  • <0.5%
  • Shorter half-life
  • CJC-1295, a growth hormone-releasing hormone analog, demonstrates similar injection site reaction rates (25-35%) but shows higher gastrointestinal side effects (10-15%) including nausea and increased appetite. The indirect mechanism of CJC-1295 through endogenous growth hormone release may provide a safer profile regarding hypoglycemic risk compared to direct IGF-1 receptor activation by PEG MGF.
  • Ipamorelin, a growth hormone secretagogue, presents a markedly different side effect profile with lower injection site reaction rates (15-20%) and minimal hypoglycemic risk. However, ipamorelin commonly causes increased hunger and appetite (15-25% of users), which is rarely reported with PEG MGF. The shorter half-life of ipamorelin (2-3 hours) means side effects resolve more quickly but may require more frequent dosing.
  • The key differentiating factor for PEG MGF is its extended half-life due to PEGylation, which may prolong both beneficial and adverse effects compared to native growth factors. This pharmacokinetic profile requires different management strategies and may not be suitable for individuals who prefer shorter-acting compounds with more predictable duration of effects.